0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV418.67%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.96Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Adicet Bio Stock Discussion
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
Adicet Bio, Inc. has launched a Phase 1 clinical trial for ADI-270, targeting metastatic clear cell renal cell carcinoma, marking a significant step in utilizing gamma delta CAR T cell therapies for solid tumors.
The company also began dosing a lupus nephritis patient in a trial for ADI-001, highlighting its focus on autoimmune diseases.
Preliminary data f...
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
Adicet Bio (NASDAQ: ACET) presented clinical biomarker data for ADI-001, their off-the-shelf gamma delta CAR T cell therapy, at ACR Convergence 2024.
The data showed robust tissue homing and complete CD19+ B cell depletion in secondary lymphoid tissue, with CAR T cell activation levels of 27-64% at the 1E9 do...
📊⚡️📊
Adicet Bio Announces FDA Clearance of Ind Amendment to Evaluate Adi-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases
Adicet Bio (Nasdaq: ACET) has opened enrollment for a Phase 1 clinical trial of ADI-001 in autoimmune diseases. The trial will focus on lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV). Enrollment is currently open for LN patients, with SLE, SSc, and AAV enrollment expected ...
Adicet Bio Inc - FDA Grants Fast Track Designation to Adi-001 for Ln
No comment yet